natgillin/translations-raw huggingface dataset:
The European Medicines Agency decided that Credelio's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Credelio večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Credelio
Druge informacije o zdravilu Credelio
Lotilaner kills fleas before they can lay eggs and so helps to reduce contamination of the animal's environment.
Lotilaner ubije bolhe, preden te lahko izležejo jajčeca, in tako pomaga zmanjšati kontaminacijo okolja živali.
Credelio is effective for one month and treatment can be repeated every month.
Zdravilo Credelio učinkuje en mesec, zdravljenje pa se lahko ponovi vsak mesec.
Because ticks must start feeding on the animal in order to be killed by the medicine, the risk of transmission of diseases that they may carry cannot be excluded.
Ker se morajo klopi začeti hraniti s krvjo živali, da bi jih zdravilo lahko uničilo, ni mogoče izključiti tveganja za prenos bolezni, s katerimi so morda okuženi.
Why is Credelio authorised in the EU?
Zakaj je zdravilo Credelio odobreno v EU?
This means that it kills parasites that live on the skin or in the fur of animals, such as fleas and ticks.
To pomeni, da ubije zajedavce, ki živijo na koži ali v dlaki živali, kot so na primer bolhe in klopi.
It contains the active substance lotilaner.
Vsebuje učinkovino lotilaner.
It blocks the normal movement of charged particles in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA) and glutamate, two substances that convey messages between nerves (neurotransmitters).
Zavira normalno prehajanje nabitih delcev v živčne celice in iz njih, in sicer zlasti tistih, ki so povezani z gamaaminomasleno kislino (GABA) in glutamatom, tj. snovema, ki prenašata sporočila med živci (živčna prenašalca).
Lotilaner kills these parasites that have ingested the blood by acting on their nervous system.
Lotilaner ubije zajedavce, ki so zaužili kri živali, tako da deluje na njihov živčni sistem.
An overview of Credelio and why it is authorised in the EU
Pregled zdravila Credelio in zakaj je odobreno v EU
The dose depends on the animal's weight.
Odmerek je odvisen od telesne mase živali.
What are the risks associated with Credelio?
Kakšna tveganja so povezana z zdravilom Credelio?
In order to be exposed to the active substance, fleas and ticks must have attached to the skin and commenced feeding on the animal's blood.
Da bi bili bolhe in klopi izpostavljeni učinkovini, se morajo pritrditi na kožo in se začeti hraniti s krvjo živali.
What benefits of Credelio have been shown in studies?
Kakšne koristi je zdravilo Credelio izkazalo v študijah?
The active substance in Credelio, lotilaner, acts as an ‘ectoparasiticide'.
Učinkovina v zdravilu Credelio, lotilaner, deluje kot ektoparaziticid.
What is Credelio and what is it used for?
Kaj je zdravilo Credelio in za kaj se uporablja?
Credelio is available as chewable tablets in seven different strengths (the lowest two strengths for cats, the rest for dogs) which are given to the animals with food or within 30 minutes after feeding.
Zdravilo Credelio je na voljo v obliki žvečljivih tablet s sedmimi jakostmi (najnižji dve jakosti za mačke, preostale pa za pse), ki se živalim dajejo skupaj s hrano ali v 30 minutah po njej.
For more information about using Credelio, see the package leaflet or contact your veterinarian or pharmacist.
Za več informacij glede uporabe zdravila Credelio glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Credelio can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).
Uporablja se lahko kot del zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
Credelio is a veterinary medicine used to treat flea and tick infestations in dogs and cats.
Zdravilo Credelio je zdravilo za uporabo v veterinarski medicini, ki se uporablja za zdravljenje infestacij z bolhami in klopi pri psih in mačkah.
Credelio reduced flea counts by 97% over one month and was as effective as the other medicine.
Zdravilo Credelio je v enem mesecu število bolh zmanjšalo za 97 % in je bilo enako učinkovito kot drugo zdravilo.
How does Credelio work?
Kako zdravilo Credelio deluje?
After being given to dogs, Credelio kills fleas within 4 hours and ticks within 48 hours of attachment.
Pri dajanju zdravila Credelio psom to bolhe ubije v štirih urah, klope pa v 48 urah po prisesanju.
After being given to cats, Credelio kills fleas within 12 hours and ticks within 24 hours of attachment.
Pri dajanju zdravila mačkam to bolhe ubije v 12 urah, klope pa v 24 urah po prisesanju.
How is Credelio used?
Kako se zdravilo Credelio uporablja?
In a small field study involving dogs with ticks, 47 dogs were treated once with Credelio and 35 dogs were treated with a spot-on medicine containing fipronil and another active substance, (s)-methoprene.
V manjši terenski študiji, ki je vključevala pse s klopi, so 47 psov enkrat zdravili z zdravilom Credelio, 35 psov pa z zdravilom za kožni nanos, ki vsebuje fipronil in drugo učinkovino, (s)-metopren.
The study showed Credelio to be as effective as the other medicine in reducing tick counts over four weeks and tick counts were reduced by 100% for Credelio treated dogs.
Študija je pokazala, da je zdravilo Credelio pri zmanjševanju števila klopov v štiritedenskem obdobju enako učinkovito kot drugo zdravilo, in sicer se je število klopov pri psih, zdravljenih z zdravilom Credelio, zmanjšalo za 100 %.
In a one month study involving cats with fleas, 121 cats were treated with Credelio and 61 cats with a spot-on medicine containing fipronil and (s)-methoprene.
V enomesečni študiji, ki je vključevala mačke z bolhami, je bilo 121 mačk zdravljenih z zdravilom Credelio, 61 mačk pa z zdravilom za kožni nanos, ki vsebuje fipronil in (s)-metopren.
In a 12-week field study involving dogs with fleas, 128 dogs were treated with Credelio every four weeks and 64 dogs with a spot-on medicine containing fipronil, another medicine to treat flea infestation.
V 12-tedenski terenski študiji, ki je vključevala pse z bolhami, so 128 psov zdravili z zdravilom Credelio vsake štiri tedne, 64 psov pa z zdravilom za kožni nanos, ki vsebuje fipronil, tj. drugim zdravilom za zdravljenje infestacij z bolhami.
Credelio was as effective as the other medicine in reducing tick counts and reduced tick counts by 99% during the study.
Zdravilo Credelio je bilo pri zmanjševanju števila klopov enako učinkovito kot drugo zdravilo, in sicer se je število klopov med študijo zmanjšalo za 99 %.
A second larger field study of dogs with ticks involved 127 dogs treated with Credelio monthly for 3 months whilst 68 dogs were treated with a spot-on medicine containing fipronil and (s)-methoprene.
Druga, večja terenska študija pri psih s klopi je vključevala 127 psov, ki so bili v obdobju treh mesecev enkrat mesečno zdravljeni z zdravilom Credelio, in 68 psov, zdravljenih z zdravilom za kožni nanos, ki vsebuje fipronil in (s)-metopren.
In a further three month study involving cats with ticks, 112 cats were treated with Credelio every month and 57 cats with a spot-on medicine containing fipronil.
V drugi, trimesečni študiji z mačkami s klopi je bilo 112 mačk enkrat mesečno zdravljenih z zdravilom Credelio, 57 mačk pa z zdravilom za kožni nanos, ki vsebuje fipronil.
The study showed Credelio to be as effective as the other medicine in reducing the flea counts over the 12 weeks and dogs treated with Credelio had flea counts reduced by 99%.
Študija je pokazala, da je zdravilo Credelio pri zmanjševanju števila bolh v 12-tedenskem obdobju enako učinkovito kot drugo zdravilo, in sicer se je število bolh pri psih, zdravljenih z zdravilom Credelio, zmanjšalo za 99 %.
MA (EU) Numbers
Številka MA (EU)
Pack size blister (alu/alu) 30 tablets blister (alu/alu) 90 (3 x 30) tablets (multipack)
90 (3 x 30) tablet (večje pakiranje)
You should take your medicine regularly at the same time each day.
Zdravilo jemljite redno, vsak dan ob istem času.
MARKETING AUTHORISATION NUMBER(S) EU/1/10/649/001-016
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/10/649/001-016
• Your doctor may order blood tests
• bo vaš zdravnik morda naročil preiskave krvi.
This may be detectable via blood or urine tests.
To je mogoče ugotoviti s preiskavami krvi ali urina.
Changes in levels of certain substances in your blood or urine.
• spremembe ravni določenih snovi v krvi ali urinu.
Some of the side effects may be serious.
Nekateri neželeni učinki so lahko resni.
Not applicable.
ni priporočena.
TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis.
TTP je potencialno usodno stanje, ki zahteva takojšnje zdravljenje vključno s plazmaferezo.
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) , not known (cannot be estimated from the available data).
Njihova pogostnost je navedena z upoštevanjem naslednjega dogovora: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznani (ni mogoče oceniti iz razpoložljivih podatkov).
An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Občasna uporaba acetilsalicilne kisline (ne več kot 1.000 mg v obdobju 24 ur) na splošno ne povzroča težav, vendar se morate v primeru dolgotrajne uporabe v drugih okoliščinah pogovoriti s svojim zdravnikom.
Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not clear whether the differences in relative risk reduction across qualifying conditions are real, or a result of chance.
Ker študija CAPRIE ni bila načrtovana za oceno učinkovitosti v posameznih podskupinah, ni jasno, ali so razlike pri zmanjšanju relativnega tveganja glede na vključitvene pogoje resnične ali slučajne.
This is linked to the way that your medicine works.
To je povezano z načinom delovanja zdravila.
Any remaining tablets should be discarded at the end of this period.
Preostale tablete je potrebno odstraniti po preteku tega obdobja.
• You should tell your doctor if surgery (including dental) is planned
• morate zdravniku povedati, če načrtujete operativni poseg (vključno z zobozdravstvenim posegom).
These may be due to a decrease of some blood cells
To so lahko znaki zmanjšanja števila nekaterih krvnih celic.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Študije pri živalih ne kažejo neposrednih ali posrednih škodljivih vplivov na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte poglavje 5.3).
BN22 9AG East Sussex United Kingdom
BN22 9AG East Sussex Velika Britanija
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
To je povezano z načinom delovanja vašega zdravila, saj le-to preprečuje strjevanje krvi.
Consequently, a direct effect (slight toxicity), or an indirect effect (low palatability) cannot be excluded.
Neposrednega (blaga toksičnost) ali posrednega (neprijeten okus) učinka zato ni mogoče izključiti.
You can take it with or without food.
lahko jemljete s hrano ali brez nje.
In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after acute ischaemic stroke.
Zaradi pomanjkanja podatkov, klopidogrela ne moremo priporočati v prvih 7 dneh po akutni ishemični kapi.
The most common side effect (affects 1 to 10 users in 100) reported for medicines containing clopidogrel is bleeding.
Najpogostejši neželeni učinek (pojavi se pri 1 do 10 bolnikih na 100 bolnikov), o katerem so poročali ob jemanju zdravil, ki vsebujejo klopidogrel, je krvavitev.
Patients should be followed carefully for any signs of bleeding including occult bleeding, especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery.
Bolnike je potrebno skrbno spremljati zaradi znakov krvavitve, vključno s prikrito krvavitvijo, zlasti prve tedne zdravljenja in/ali po invazivnih kardioloških postopkih ali kirurških posegih.
Talk to your doctor if you are using or have recently used any of the following medicines:
Obvestite svojega zdravnika, če jemljete ali ste pred kratkim jemali katero od naslednjih zdravil:
If you suffer from any of the following symptoms you should contact your doctor immediately:
Če se pri vas pojavi kateri od sledečih simptomov, se nemudoma posvetujte z zdravnikom:
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
Rezultati, pridobljeni pri populacijah z različnimi karakteristikami (npr. nestabilna angina, MI brez Q zobca, nizka do visoka raven tveganja, diabetes, potreba po revaskularizaciji, starost, spol, itd), so skladni z rezultati primarne analize.
In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients ≤75 years.
Poleg tega analiza podskupin glede na starost nakazuje, da so koristi klopidogrela pri bolnikih, starejših od 75 let, manjše od tistih, ki so jih opazili pri bolnikih ≤ 75 let.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
DATE OF REVISION OF THE TEXT <DD month YYYY>
DATUM ZADNJE REVIZIJE BESEDILA <{DD. mesec LLLL}>
For the HDPE bottle presentation chemical and physical in-use stability have been demonstrated for:
Kemična in fizikalna stabilnost zdravila v HDPE steklenički je bila dokazana za naslednje obdobje:
• You have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days
• Če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih sedmih dneh.
Patients should inform physicians and dentists that they are taking clopidogrel before any surgery is scheduled and before any new medicinal product is taken.
Bolniki morajo zdravnike in zobozdravnike obvestiti, da jemljejo klopidogrel, preden določijo termin za kakršenkoli kirurški poseg in preden začnejo jemati katerokoli novo zdravilo.
Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (seesection 5.1).
Podatki iz kliničnih preskušanj podpirajo uporabo do 12 mesecev, največjo korist pa so opazili po 3 mesecih (glejte poglavje 5.1).
Put the tablet in your mouth and swallow with water or another liquid.
Tableto položitev v usta in jo pogoltnite skupaj z vodo ali drugo tekočino.
• You have had an allergy or reaction to any medicine used to treat your disease.
• Če ste imeli alergijo ali alergijsko reakcijo na katero koli zdravilo, ki ste ga jemali.
Each tablet contains 62.16 mg lactose monohydrate and 10 mg hydrogenated castor oil.
Ena tableta vsebuje 62,16 mg laktoze monohidrata in 10 mg hidrogeniranega ricinusovega olja.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Vendar pa je zaradi pomanjkanja študij o interakcijah z drugimi nesteroidnimi protivnetnimi zdravili trenutno nejasno, ali povečano tveganje za pojav gastrointestinalne krvavitve obstaja pri vseh nesteroidnih protivnetnih zdravilih.
TEVA Santé SA Rue Bellocier 89107 Sens France
TEVA Santé SA Rue Bellocier 89107 Sens Francija
Pregnancy and breast-feeding It is preferable not to use this medicine during pregnancy.
Nosečnost in dojenje Priporočljivo je, da tega zdravila v nosečnosti ne uporabljate.
Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment.
Krvavitve so bile najpogosteje opisan učinek tako v kliničnih študijah kot v obdobju trženja zdravila, kjer so se najpogosteje pojavile prvi mesec zdravljenja.
If you cut or injure yourself, it may take slightly longer than usual for bleeding to stop.
Če se urežete ali poškodujete, lahko traja nekoliko dlje kot običajno, da se krvavitev ustavi.
• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na klopidogrel ali katerokoli sestavino tega zdravila (navedno v poglavju 6).
Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).
Klopidogrel podaljša čas krvavitve in ga je potrebno uporabljati previdno pri bolnikih z lezijami, ki so nagnjene h krvavitvi (zlasti gastrointestinalne in intraokularne).
E.g. ibuprofen, diclofenac and meloxicam.
Na primer ibuprofen, diklofenak in meloksikam.
TEVA Santé SA, Rue Bellocier, 89107 Sens, France
TEVA Santé SA, Rue Bellocier, 89107 Sens, Francija
Sore mouth (stomatitis)
• vnetje v ustih (stomatitis),
When given to lactating rats, clopidogrel caused a slight delay in the development of the offspring.
Ko so klopidogrel dajali podganam v obdobju laktacije, je povzročil rahlo upočasnitev razvoja mladičev.
If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery.
Če ima bolnik predviden kirurški poseg in antitrombotični učinek začasno ni zaželen, je potrebno zdravljenje s klopidogrelom prenehati 7 dni pred kirurškim posegom.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
Trombotična trombocitopenična purpura (TTP) O trombotični trombocitopenični purpuri (TTP) so po uporabi klopidogrela poročali zelo redko, včasih po kratki izpostavljenosti.
• Medicines used to break down blood clots (e.g. alteplase and streptokinase).
• zdravila, ki razgrajujejo krvne strdke (npr. alteplaza in streptokinaza).
Do not use this medicine after the expiry date which is stated on the outer carton, bottle or blister after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, steklenički in pretisnem omotu.
• You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
• ste doživeli hudo obliko bolečine v prsih, znano kot “nestabilna angina” ali “miokardni infarkt” (srčni napad).
- Bottles contain 30 or 100 film-coated tablets.
- Stekleničke vsebujejo 30 ali 100 filmsko obloženih tablet.
Analysis of total mortality as a secondary endpoint did not show any significant difference between clopidogrel (5.8%) and ASA (6.0%).
Analiza skupne umrljivosti kot sekundarnega opazovanega dogodka ni pokazala značilne razlike med klopidogrelom (5,8 %) in acetilsalicilno kislino (6,0 %).
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction.
V podskupini z miokardnim infarktom je večina bolnikov prejemala acetilsalicilno kislino prvih nekaj dni po akutnem miokardnem infarktu.
• You have hardening of the arteries and have recently suffered from a heart attack, a stroke or have a condition known as “peripheral arterial disease” (diseases of the blood vessels except those in the brain and heart).
• Imate stanje otrdelih arterij in ste pred kratkim doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (obolenje krvnih žil z izjemo tistih v možganih in srcu).
Approximately 88% of patients received concomitant ASA (range of 1 to 23 mg/kg/day).
Približno 88 % bolnikov je sočasno prejemalo acetilsalicilno kislino (v razponu od 1 do 23 mg/kg/dan).
Prevention of atherothrombotic events Clopidogrel is indicated in:
Preprečevanje aterotrombotičnih dogodkov: Klopidogrel je indiciran pri:
In addition to clinical studies experience, adverse reactions have been spontaneously reported.
Poleg neželenih učinkov v kliničnih študijah so bile neželene reakcije prijavljene tudi spontano.
It is unknown whether clopidogrel is excreted in human breast milk.
Ni znano ali se klopidogrel pri človeku izloča v materino mleko.
Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below.
Neželene reakcije, ki so se pojavile v kliničnih študijah ali o katerih so poročali spontano, so naštete v spodnji razpredelnici.
In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the authorised tablet
V študiji relativne biološke uporabnosti pri odraslih je imela pripravljena raztopina klopidogrela podoben obseg in rahlo večjo hitrost absorpcije glavnega krožečega (neaktivnega) presnovka kakor odobrena tableta.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group].
Ta korist se je pokazala v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom, in 363 (5,8 %) v skupini s placebom].
Therapeutic experience with clopidogrel is limited in patients with renal impairment.
Terapevtske izkušnje s klopidogrelom so pri bolnikih z ledvično okvaro omejene.
If you take more Clopidogrel Teva Pharma B.V. than you should If you (or someone else) swallow a lot of the tablets all together, or if you think a child has swallowed any of the tablets, contact your nearest hospital casualty department or your doctor immediately.
Če ste vzeli večji odmerek zdravila Klopidogrel Teva Pharma B.V., kot bi smeli Če vi (ali kdorkoli drug) meni, da ste pomotoma vzeli preveliko število tablet ali mislite, da jih je pogoltnil otrok, nemudoma obiščite najbližji oddelek nujne medicinske pomoči ali o tem nemudoma obvestite svojega zdravnika.
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Sočasno zdravljenje z drugimi zdravili: Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).
Zaradi tveganja za pojav krvavitev in hematoloških neželenih učinkov je potrebno takoj preučiti potrebo po določanju števila krvnih celic in/ali drugih ustreznih preiskav, kadar se v obdobju zdravljenja pojavijo klinični simptomi, ki nakazujejo krvavitev (glejte poglavje 4.8).
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
Farmakoterapevtska skupina: Zaviralci agregacije trombocitov brez heparina Oznaka ATC: B01AC04
• Heparin (medicine used to prevent blood clotting).
• heparin (zdravilo, ki se uporablja za preprečevanje strjevanja krvi).
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY, COMMIT in ACTIVE-A, so predstavljeni spodaj.
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake.
Vseeno sočasna uporaba 500 mg acetilsalicilne kisline dvakrat na dan en dan ni pomembno povečala podaljšanja časa krvavitve, sprožene z jemanjem klopidogrela.